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Toxicity and Carcinogenicity of Potassium
Bromate-A New Renal Carcinogen
by Yuji Kurokawa,* Akihiko Maekawa,t Michihito
Takahashi,t and Yuzo Hayashit
Potassium bromate (KBrO3) is an oxidizing agent that has been used as a food additive, mainly in the
bread-making process. Although adverse effects are not evident in animals fed bread-based diets made
from flour treated with KBrO3, the agent is carcinogenic in rats and nephrotoxic in both man and exper-
imental animals when given orally. It has been demonstrated that KBrO3 induces renal cell tumors,
mesotheliomas oftheperitoneum, andfollicularcell tumors ofthe thyroid. In addition, experiments aimed
at elucidating the mode of carcinogenic action have revealed that KBrO3 is a complete carcinogen, pos-
sessing both initiating and promoting activities for rat renal tumorigenesis. However, the potential seems
to be weak in mice and hamsters. In contrast to its weak mutagenic activity in microbial assays, KBrO3
showedrelatively strongpotential inducingchromosome aberrations both in vitro and in vivo. Glutathione
and cysteine degrade KBrO3 in vitro; in turn, the KBrO3 has inhibitory effects on inducing lipid peroxi-
dation in the rat kidney. Active oxygen radicals generated from KBrO3 were implicated in its toxic and
carcinogenic effects, especially because KBrO3 produced 8-hydroxydeoxyguanosine in the rat kidney. A
wide range ofdata from applications ofvarious analytical methods are now available for risk assessment
purposes.
Introduction
In the mid-1970s, the close correlation between mu-
tagenicity and carcinogenicity of many chemicals be-
came striking to those engaged in studies on carcino-
genesis. Accordingly, a cooperative program was
designed to evaluate the predictability of mutagenicity
tests for carcinogenicity. This program commenced in
1974 under the auspices of the Ministry of Health and
Welfare ofJapan (1,2). To date, 85 bioassays using rats
and/or mice have been conducted on 51 chemicals, in-
cluding medical drugs, pesticides, and food additives.
KBrO3 was selected as one of the chemicals for car-
cinogenicitytestingbecause ofits positive mutagenicity
and widespread use as a food additive. It is used mainly
inthematuration processofflourbecauseofitsoxidizing
properties. In 1978, long-term bioassays ofKBrO3 were
startedbyusingrats andmice; as aresult, thisoxidizing
agent was found to be carcinogenic in rats after 2 years
of oral administration (3).
The present review covers the various toxicological
studies that have mainly been conducted in our labo-
ratory (4-19), with the aim of elucidating the mode of
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action and mechanisms of KBrO3 carcinogenicity. The
International Agency for Research on Cancer (IARC)
recently evaluated all of the data on KBrO3 and con-
cluded, "There is sufficient evidence for the carcino-
genicity of KBrO3 in experimental animals. No data
were available on the carcinogenicity of KBrO3 to hu-
mans" (20). KBrO3 has been also classified as a com-
pound belonging to the group 2B, a possible human
carcinogen (21).
Chemistry and Use
Since this paper is primarily intended as a review of
biologicaldata on KBrO3, we encouragereaders torefer
to the International Agency for Research on Cancer
(IARC) Monograph for further details on the subjects
covered in this chapter (20).
Chemistry and Production
Potassium bromate (KBrO3, CAS No. 7758-01-2, mo-
lecular weight 167.01; density, 3.27) exists as white
crystals, crystalline powder, or granules. It is highly
soluble in water (7.5 g/100 mL at 25°C; 49.8 g/100 mL
at 100°C), slightly soluble in ethanol, and almost insol-
uble inacetone; itis verystablewhendissolvedinwater
at room temperature. KBrO3 decomposes at tempera-
tures above 370°C (melting point: 350°C), with the ev-
olution ofoxygen and toxic fumes containing potassiumKUROKAWA ETAL.
oxide and BrK; it reacts vigorously as astrongoxidizing
agent with organic materials.
KBrO3 can be produced by passing bromine through
a solution of potassium hydroxide. However, the com-
pound is manufactured mainly by large-scale industrial
electrolytic processes.
Occupational exposure toKBrO3 occursmainlyinpro-
duction plants during packaging processes in which
areas in excess of 100 mg/m3 require the use of a dust
respirator.
Use
KBrO3 has been used primarily as a maturing agent
forflourand as adough conditionerinthe bread-making
process for over 50 years (22-24), and this application
is now used worldwide. Food additive-grade KBrO3 is
specified to contain KBrO3 at levels of 99.0 to 101.0%
after drying. InJapan, allowable limits are specified to
be no more than 4 ppm for arsenic and heavy metals
and 10 ppm for lead. The levels of contaminants in
KBrO3 used in our studies were within an acceptable
range (6).
TheJoint Food and Agricultural Organization (FAO)/
World Health Organization Expert Committee on Food
Additives (JECFA) has temporarily recommended a
maximum level of 75 ppm of KBrO3 for treating flour,
provided that baking products prepared from such
treated flour contain negligible residues ofKBrO3 (25).
In Japan, the level has been set at 30 ppm under the
same conditions as for JECFA (26). The effects of
KBrO3 on various nutritional values of the flour are
reported to be negligible (22).
In the past, especially in Japan, KBrO3 was used to
improve the quality offish-paste products (Kamaboko)
at concentrations less than 270 mg/kg. However, this
application of KBrO3 is no longer allowed (26).
As nonfood usage, KBrO3 has been introduced as an
oxidizing agent, a primary standard, and a brominating
agentinanalyticalchemistry. Itsoxidizingpropertyhas
furtherbeenusedinhomepermanent-waveneutralizing
compounds at concentrations ofbetween 5 to 25% at pH
4 to 9, together with sodium bromate, sodium perbor-
ate, or hydrogen peroxide (27).
Analysis
KBrO3 can be determined by iodometric titration
methods, photometric ion chromatography (28-31), and
by high-performance liquid chromatography (HPLC)
(32). In Great Britain levels ofKBrO3 in bread assessed
bytheiodometrictitrationmethodwerenegligiblewhen
the dough was treated with KBrO3 < 50 ppm (33,34).
Furthermore, bromate could not be detected by ion
chromatography in bread treated with < 50 ppm of
KBrO3 (28). Recently it was reported that the detection
limit ofa newly developed HPLC method, based on the
formation of triiodide ion by the reduction of bromate
and iodide (0.05 ppm) (32), is much lower than that
detectedbyionchromatography (1 ppm) (29). However,
bromate was not detected in 10 samples of commercial
bread in Japan by this very sensitive approach (32).
Toxicity
Acute Toxicity in Experimental Animals
Groups of five males and five females each of F344
rats, B6C3F1 mice, and Syrian golden hamsters were
given a single intragastric (IG) administration ofKBrO3
and observed for 7 days (9). In all species given high
doses (900-700 mg/kgofbodyweight), two-thirds ofthe
animals died within3 hrofthetreatment; the remaining
one-third survived up to 48 hr. Major toxic signs and
symptoms observed were animals lying in a prone po-
sition, suppression oflocomotor movement, ataxic gait,
tachypnea, hypothermia, diarrhea, lacrimation, and pil-
oerection. At autopsy the major findings were strong
hyperemiaoftheglandularstomachmucosaand conges-
tion of the lung. Microscopically, epithelial dilatation
and desquamation ofthe distal convoluted tubules were
noted in rats as early as 1 hr after KBrO3 administra-
tion. Necrosis anddegenerative changesofthe proximal
tubular epithelium were observed after 3 hr, and re-
generative changes of the tubular epithelium occurred
within 48 hr, becoming more extensive after 2 weeks.
In mice and hamsters, however, these histological
changes were observed later and to alesser degree. No
glomerular lesions were found in any ofthe species ex-
amined.
LD50 values calculated by the Probit method are
shown in Table 1. Although LD50 values were higher in
females than in males in all species examined, there
were no marked species differences. The fact that the
values were distributed in the range of around 300 to
500 mg/kg of body weight in all three species implies
thatKBrO3shouldbe classified as averytoxicchemical.
Furthermore, in Wistar rats the LD50 values for both
sexes were reportedly to be approximately 160 to 180
mg/kgbodyweight(Kawachi, personalcommunication).
An increase in the levels ofcholesterin and phospho-
lipids was observed inthebrain andkidneyinmiceafter
a single IG administration of KBrO3 (35).
Acute Toxicity in Humans
Case reports on KBrO3 poisoning in humans are not
uncommon because of the widespread use of the com-
pound in home permanent-wavingkits. However, there
seem to be different geographical trends in occurrence.
In Western countries most poison cases are by acciden-
Table 1. LD50 values in three species.
LD50, mg/kg body weight
Species Strain Male Female
Rat F344 400(348-460)a 495(446-549)
Mouse B6C3F1 280(250-314) 355(311-405)
Hamster Syrian golden 388(318-473) 460(400-529)
aNumbers in parentheses are 95% confidence limits.
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tal ingestion, mainly among children; in Japan, KBrO3
is more often ingested for attempted suicide by young
women, especially hairdressers (Table 2). The lethal
dose of KBrO3 in man has variously been estimated at
5 to 50 mg/kg of body weight (36) or 200 to 500 mg/kg
ofbody weight (37). Inreported casesthe actual amount
ingested ranged from 12 to 50 g, and 9 out of24 adults
died 3 to 5 days after ingestion (35,37).
Inthe acute phase ofpoisoning, vomitinganddiarrhea
with abdominal pain are the main symptoms. Subse-
quent features include oliguria, anuria, deafness, ver-
tigo, hypotension, depression ofthecentral nervous sys-
tem, and thrombocytopenia. Clinically, acute renal
failure is evidenced by the impairment ofvarious renal
functions and an associated development of hemolytic
uremic syndrome (36). On biopsy ofthe kidney atrophy,
necrosis, degeneration, and regeneration of the proxi-
mal tubular epithelium have often been reported. In the
later stages, however, sclerosis of the glomeruli and
interstitial fibrosis become evident; cardiotoxicity and
hepatotoxicity have also been reported (37). Although
bromate is converted to bromide in vivo, it is clear that
observed effects in different organs can be attributed
to bromate ions themselves, because only very low
serum bromide levels were evident in the patients in-
vestigated.
The curious relationship between nephrotoxicity and
ototoxicity induced by aminoglycoside antibiotics
(streptomycin, kanamycin, neomycin) and diuretics
(ethacrynic acid and furosemide) is well known. Since
KBrO3 has been added to the list of substances that
selectively attack these two organs in man (39-41),
some experiments were conducted to determine the
cause.
Ototoxicity of KBrO3 and NaBrO3 was studied in
guinea pigs after IP injection at a daily dose of 10 to 20
mg/kgbodyweightfor 10to20days (41). Histologically,
degeneration of the cochlear sensory cells, particularly
of the outer hair cells of the inner ear was observed.
At the same time, nephrotoxic effects of KBrO3 and
NaBrO3 were also confirmed in guinea pigs. The fact
that the kidney and the inner ear are both highly effi-
cient systems for transport of water and electrolytes
mightexplainthecoincidental occurrenceofnephro-and
ototoxicity by these chemicals (40).
Subacute Toxicity
Administration of KBrO3 in Drinking Water of
Mice. Groups of 10 male and 10 female B6C3F1 mice
were given KBrO3 at doses of4000, 2000, 1000, 500 and
250 ppm for 10 weeks (15). Doses > 2000 ppm were not
palatable. No treatment-associated deaths of animals
given < 1000 ppm or particular histopathological
changes attributed to KBrO3 administration were ob-
served.
Table 2. Case reports of KBrO3 poisoning.a
Case Age, Renal Onset of Blood
no. years Sex Occupation Circumstances Dosage failure Deafness deafness pressure Prognosis
1 1.5 M Accident + Died
2 2.5 M Accident 1/2 cup + 96/54
3 3 M Accident +
4 2.5 F Accident 1/3 CUp +
5 3 F Accident 70 g
6 14 F Accident +
7 3 M Accident 4 g + 85/45
8 4 M Accident
9 2 M Accident 1/2 cup
10 1.8 M Accident + Died
11 Adult F Accident + +
12 Adult F Accident + + Died
13 Unknown Suicide +
14 18 F Hairdresser Suicide 2 g - - 88/50
15 21 F Suicide + + Died
16 39 F Hairdresser Suicide 15 g + + 6 hr 60/30
17 21 F Suicide + + Died
18 23 F 10 g + + Died
19 29 F Hairdresser Suicide 25 g + + 16 hr 120/70 Died
20 47 F Hairdresser 25 g + + Died
21 19 F Hairdresser Suicide 25 g + - 60/40
22 18 F Student Suicide 40 g + + 4 hr 96/50 Died
23 29 F Hairdresser Suicide + + 6 hr 88/60 Died
24 34 M 30 g + +
25 25 F Hairdresser Suicide 15 g + + 130/20
26 19 F Hairdresser Suicide 15 g + - 150/70
27 30 F Hairdresser Suicide 25 g + + 8 hr 88/70 Died
28 18 M Student Suicide 6 g + + 4 hr 130/60
29 30 F Housewife Suicide 15 g + + 12 hr
30 22 F Hairdresser Suicide 10 g + + 12 hr 90/70
31 6 M 0.5 g + + 90/60
aModified from Matsumoto (39).
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Study of Rats Administered KBrO3 in Drinking
Water. Groups of 10 male and 10 female F344 rats
were administered KBrO3 at doses of10000, 5000, 2500,
1250, 600, 300, and 150 ppm for 13 weeks (Onclera,
unpublished data). Doses : 2500 ppm were not palat-
able. Allanimals given > 1250 ppmdied within7weeks,
whereas all animals given
- 600 ppm survived for 13
weeks. A significant inhibition ofbody weight increase
was observed in males given 1250 or 600 ppm. Signifi-
cantly elevated levels ofGOT, GPT, LDH, ALP, BUN,
serum-Na and Ch-E were noted in rats of both sexes
given 600 ppm. Serum-K levels were also significantly
decreased. Many various-sized droplets stained
strongly with eosin were observed in the cytoplasm of
the proximal tubular epithelium in treated males. Ex-
tensive regenerative changes were seen in the renal
tubules.
For analyzing the droplets observed in the renal tu-
bules, groups offive male F344 rats were given 600 ppm
KBrO3 orally for 12 weeks (10). In renal tubules, var-
ious-sized droplets were found as early as 4 weeks after
the treatment began (Fig. 1). The incidence ofthe drop-
lets decreased to control levels 4 weeks after terminat-
ing the treatment. These droplets were positive for
Azan, negative forPAS, andpartiallypositiveforhemo-
globin staining; they were also observed in control rats,
though to a far lesser degree. As observed by electron
microscopy, the droplets demonstrated high electron
density and were surrounded by a limiting membrane
layer (Fig. 2). The origin of these droplets seemed to
be the lysosomes, and they seemed to result from ma-
terial being reabsorbed. From the morphological char-
acteristics, it was concluded that these droplets were
eosinophilic bodies rather than hyaline droplets (42,43).
Recently, droplets showingsimilarcharacteristics were
observed in the kidneys of rats given decalin, 2,2,4-
trimethylpentane, or unleaded gasoline. In these cases,
however, they were classified as hyaline droplets
(44,46). U2u-Globulin, which is specific for the kidneys
ofmale rats, seems to be involved in the appearance of
the hyaline droplets. In preliminary studies the gen-
FIGURE 1. Droplets strongly stained by eosin in the cytoplasm of
proximal renal tubules of rats given KBrO3 for 4 weeks.
FIGURE 2. By electron microscopy, various-sized electron-dense
droplets are observed surrounded by a limiting membrane layer.
erationofeosinophilicbodies inratstreatedwith KBrO3
was inhibited by castration, ovariectomy, or treatment
with cysteine (47,48). Numerous lipofuscin pigments
were also observed in the proximal tubular epithelium
of treated rats.
Administration ofKBrO3-Treated Flour or Bread.
Japanese researchers have concentrated on the effects
ofadministration ofKBrO3 dissolved in water, whereas
researchers in Great Britain fed animals KBrO3-treated
flour itself, or bread made from flour treated with
KBrO3 (22). Eighteen rats, three dogs, and three mon-
keys were fed a diet containing 84% flour treated with
KBrO3 at a level of about 75 ppm for a period of 4, 12,
and 8 weeks, respectively. No adverse effects were ob-
served in any of the species. Bread made from flour
treated with 200 ppm KBrO3 was fed to 12 rats and 2
dogs for 16 days,and flour treated with 200 ppm KBrO3
was given to rats for 10 weeks, again without any ill
effects. Similarly no clinical symptoms were apparent
in three dogs fed diets containing flour treated with 70
ppm KBrO3 for 6 weeks. Four dogs administered bread
made from flour containing 200 ppm KBrO3 for 17
months also showed no adverse effects attributable to
the diet.
Multigeneration Studies
Bread made from flour treated with 14 or 100 ppm of
KBrO3 was fed to groups of 6 male and 20 female rats
over three generations; the entire experiment lasted 10
months (22). The health, behavior, weight gain, and
reproductive performance remained normal through-
out. There were no histological abnormalities and anal-
yses ofthe brain and the liver showed no accumulation
of bromine.
Mice and rats (numbers were not specified) were fed
flour treated with 15 ppm KBrO3 over eight and five
generations, respectively. In both studies, no effects
were observed on weight gain, reproductive perfor-
mance, or survival.
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Carcinogenicity Including Chronic
Toxicity
Studies in the United Kingdom
Long-termtoxicity and carcinogenicity studiesin rats
and mice were conducted byfeeding animals with bread
treated with KBrO3 (49,50). The levels ofKBrO3chosen
for the treatment offlour were 50 and 75 ppm because
it was determined that KBrO3 was quantitatively con-
verted to bromide during the dough-mixing process
with the KBrO3 at concentrations below 75 ppm (34).
Thus, the purpose of the studies was to ascertain the
safetyofbreadmadefromKBrO3-treatedflour, inwhich
bromate levels were presumed to be negligible. The
bread made from KBrO3-treated flour was crumbed and
dried for incorporation in the diet at a 79% concentra-
tion.
Groups of90 males and 90 females ofWistar-derived
Porton strain rats and mice of the Theillers original
strain (900) were fed diets made from bread treated
with 75 ppm (high-dose group), 50 ppm (low-dose
group), or 0 ppm (control group) of KBrO3 for 104 and
80 weeks, respectively.
RatStudy. Nodifferences werenotedin appearance
or behavior between test and control rats (49). Cumu-
lative mortality rates at week 104 were 20.0%, 38.3%,
and 26.7% in males; and 30.0%, 51.7%, and 51.7% in
females in the high-dose, low-dose, and control groups,
respectively. No intergroup differences were found re-
garding food intake in either sex. No dose-related
changes in the absolute or relative organ weights were
apparent. Histopathological data are shown in Table 3.
Although not pointed out in the original report, it is
noteworthy that the occurrence of periarteritis in the
pancreas of male rats was significantly increased in a
dose-related manner. Also the various aging pathology
ofthe adrenals was significantly increased in the female
high-dose group. No dose-dependent variation in the
incidences of any tumors was apparent. Dose-related
reduction in blood glucose levels were observed in
treated rats of both sexes at week 104. There was no
retention oraccumulation ofsignificant amountsofcova-
lently bound bromine in the adipose tissue of treated
rats.
Mouse Study. General appearance and behavior
weregoodinbothtestandcontrol groups(50). Mortality
rates at week 80 were 61.8, 65.1, and 65.1% in males;
and 56.8, 48.4, and 56.8% in females for the high-dose,
low-dose, and control groups, respectively. There were
no significant differences in the mean body weights or
foodintake among groups. Normalized (weightedmean)
bromineintakes derived fromKBrO3 were2.64and 1.76
mg/kg/day in males and 2.99 and 2.03, mg/kg/day in
females forthe high- andlow-dose groups, respectively.
Significant dose-related reduction in the absolute
weights of the heart and the pituitary was found in
treated males. Absolute thyroid weights were signifi-
cantly higherinthe high-dose males. Anemia was prev-
alent in male high- and low-dose groups at 3 months.
However, no histopathological differences attributable
to the treatment were found between test and control
males. Small amounts ofbromine were detected in the
adipose tissues, i.e., at a level of 1 ppm in males ofthe
high- and low-dose groups and at a level of 2 ppm in
females of the low-dose group. Ginocchio et al. con-
cluded that there was no evidence that flour treatment
withKBrO3 affectedtheincidenceofneoplasticand non-
neoplastic lesions in the mouse study (50).
Other Studies on Rats and Mice. Groups of 90
Table 3. Results of histopathological examination in rats given diets based on bread made from flour treated with KBrO3.a
KBrO3 dose, ppm
Males Females
Pathology 0 (88)b 50 (90) 75 (88) 0 (89) 50 (89) 75 (88)
Nonneoplastic lesions
Pancreas
Pancreatitis 4 0 2 2 2 3
Periarteritis 2 9 12* 9 15 10
Giant islet 0 2 0 2 1 0
Adrenals
Various aging pathology 23 35 35 47 42 71$
Testes
Periarteritis 8 8 8
Uterus
Cystic endometrial hypertrophy or cystic dilatation 17 8 6
Neoplastic lesions
Tumors
Benign 33 42 33 43 60 50
Malignant 4 6 4 6 3 3
Total tumors 37 48 37 49 63t 53
aModified from Fisher et al. (49).
bNumbers in parentheses are numbers of rats examined.
*p < 0.05.
tp < 0.01.
tp < 0.001.
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males and 90females rats andmice were fed bread made
from two kinds of flour, namely, a) flour treated with
50 ppm KBrO3, 30 ppm ascorbic acid, and 50 ppm ben-
zoyl peroxide; and b) flour treated with 50 ppm KBrO3,
30 ppm ascorbic acid, 50 ppm benzoyl peroxide, and 15
ppm chlorine dioxide (49,50). Although these findings
were not emphasized in the literature, two significant
findings were noted in rats given the latter diet. The
incidence of periarteritis in the pancreas in males
(13.3%, 12/90) was significantly increased over controls
(2.3%, 2/88); and the rates were markedly elevated for
the ocurrence ofvarious agingpathology in the adrenals
at 51.1% (46/90) and 75.0% (66/88), inmales andfemales,
respectively.
Studies in Japan
After learning about the United Kingdom's results
on long-term studies in which animals were fed a bread
basal diet prepared from KBrO3-treated flour, we be-
came interested in the possible carcinogenicity of the
chemical. Hence, KBrO3 was given to animals by oral
administration as a drinking water supplement at high
concentrations, the highest doses being the maximum
tolerated doses. Detailed protocols for the experiments
have been described (3-6,8-10,13-15).
Carcinogenicity Tests inRats (3,4,6,9,15). Groups
of53 males and 53 females ofF344 rats received KBrO3
for 110 weeks at concentrations of 500 and 250 ppm in
the drinking water. However, for males treated at the
500 ppm level, the dose was reduced to 400 ppm at week
60, because exposure to 500 ppm caused too great an
inhibition of growth.
Dead or moribund rats were found earlier among
males given 500 ppm than in other groups. Mean sur-
vival time in males given 500 ppm (88.1 weeks) was
significantly shorter than that in controls (104.5 weeks).
In females, the survival rates of treated and control
groups were very similar. Daily intakes of KBrO3
(mg/kg body weight) were 27.7 and 12.5 in males and
25.5 and 12.5 in females in the high- and low-dose
groups, respectively.
We suspected the kidney to be the target organ dur-
ing the observational period by preliminary histological
examination. Therefore, 10 to 15 step-serial sections
were examined from each kidney. This procedure is not
routine for pathological assessment in carcinogenicity
studies. The results were high incidences of renal cell
tumors (RCTs) in dosed males and females. Data for
separated and combined incidences of renal adenocar-
cinomas and adenomas are summarized in Table 4. Sig-
nificant increases were evident for both sexes, as com-
pared to the control group values. The incidences of
RCT on the basis ofroutine microscopic examinations,
in which one slide per kidney was checked, also showed
significant differences from those of controls (i.e., 56,
30, and 2% inmales; and 40, 10, and 0% in females given
500, 250, and 0 ppm KBrO3, respectively, p < 0.01,
except in females given 250 ppm), as shown in our first
report (3). Although lesions were found much earlier in
high-dose males than they were in the other groups,
RCTs did not appear to be the main cause of death in
the experiment. Dysplastic foci (DF), which are pre-
neoplastic lesions for RCT, were observed in almost all
of the treated rats of both sexes. Other tumors found
in the kidney were two transitional cell papillomas, two
transitional cell carcinomas, and one angiosarcoma in
treated rats and one liposarcoma in a control rat.
Tumors of the peritoneum, all diagnosed as mesoth-
eliomas, also occurred at asignificantly higherincidence
in male rats given 250 or 500 ppm than in the controls
(Table 5). On the other hand, no mesotheliomas were
observed in either treated or control female rats. The
mesotheliomas usually resulted inimplantation onto the
surfaces of various abdominal organs, with massive
hemorrhagic ascites causing severe anemia leading to
early death. Findings of nonneoplastic lesions of the
kidney are described in the section "Pathological Le-
sions of the Kidney after KBrO3 Administration."
Significantlydecreased values werefoundinGPT, the
albumin/globulin (A/G) ratio, serum K, and Ch-E in fe-
males that were treated with 500 ppm KBrO3. Also, we
noted that BUN levels were slightly increased in
treated rats. There were no significant differences in
the red blood cell (RBC) counts.
We concluded from the above findings that clear evi-
Table 4. Incidences of renal cell tumors (RCT) and dysplastic foci (DF) in male and female F344 rats in the
carcinogenicity test of KBrO3.
Number of rats (%) bearing
Effective number Mean induction Earliest RCT Adeno-
Group of ratsa time ± SD, week found, week RCT carcinomas Adenomas DF
Male
500 ppm 52 88.9 ± 18.9 14 46(88)* 44(85)* 5(10)t 40(77)*
250 ppm 53 103.7 ± 9.1 77 32(60)* 24(45)* 10(19)t 32(60)*
0 ppm 53 111.0 ± 0 111 3(6) 3(6) 0(0) 6(11)
Female
500 ppm 49 107.9 ± 5.6 85 39(80)* 36(69)* 9(17)t 9(17)t
250 ppm 50 107.6 ± 5.8 89 28(56)* 21(40)* 8(15)t 13(25)t
0 ppm 47 0(0) 0(0) 0(0) 0(0)
aMales and females surviving longer than 14 and 85 weeks, respectively, when the earliest RCTs were found.
p < 0.001.
tp < 0.01.
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Table 5. Incidences of mesotheliomas in male F344 rats in the
carcinogenicity test.
Mean Mesothelioma
Effective induction Earliest Number of
number of time + SD, found, tumor-bearing
Group ratsa week week rats (%)
500 ppm 46 91.0 ± 10.7 73 28(59)*
250 ppm 52 95.0 ± 14.4 72 17(33)t
Oppm 53 98.8 ± 12.1 80 6(11)
aMales surviving longer than 72 weeks when the earliest meso-
thelioma was found.
*p < 0.001.
tp < 0.05.
dence exists that when KBrO3isgivenorallyindrinking
water, it is carcinogenic in rats ofboth sexes.
Dose-Response Studies in the Rat (14). Based on
the results ofthe carcinogenicity test in rats, studies at
low doses were conducted to further characterize the
dose-response relationship (14). Groups of20 to 24 male
F344 rats were given KBrO3 orally at concentrations of
500, 250, 125, 60, 30, 15, and 0 ppm for 104 weeks.
As in the previous carcinogenicity test, the mean sur-
vival time of the animals given 500 ppm (82.8 weeks)
was significantly shorter than that of controls (103.1
weeks). However, at doses of 250 ppm or lower, the
survival rates were comparable in treated and control
groups and inhibition of body weight gain was not ap-
parent.
Renal adenocarcinomas developed in 3 of the 20 rats
given 500 ppm (Table 6), and the incidences of renal
adenomas and RCTs were significantly elevated in rats
receiving concentrations of 500, 250, and 125 ppm. A
sigmoidal curve was obtained when the incidences of
RCTs were plotted against the dose ofKBrO3 (Fig. 3).
Furthermore, significant dose-related increases in the
incidences of DF were also noted in all groups given
doses higher than 30 ppm.
Follicular adenomas and adenocarcinomas ofthe thy-
roid were found in the groups treated with 500, 250,
and 60 ppm (Table 7); the combined incidences ofbenign
and malignant follicular lesions were significantly in-
creased in rats of the 500 ppm dose group. Mesothe-
liomas ofthe peritoneum were also observed in treated
rats at doses higher than 30 ppm; again, the incidence
in animals receiving 500 ppm was significant.
Although the RCT rates in high-dose males were
somewhat lower than those in the previous carcinogen-
icity study, they were nevertheless significantly in-
creased in a dose-related manner. The yield ofRCTs in
the 125-ppm group was significantly higher than that of
controls, indicating that oral doses higher than 60 ppm
may induce RCTs after long-term treatment. The in-
cidence ofmesotheliomas ofthe peritoneum was signif-
icantlyincreased only at adose of500 ppm inthis study,
in contrast to the significantly higher rates at both 500
ppm (59%) and 250 ppm (33%) in the former test. On
the other hand, this experiment demonstrated elevated
combined incidences of follicular adenocarcinomas and
adenomas ofthe thyroid that were not observed in the
previous study (6). Although the incidence in rats given
250 ppm (15%, 3/20) was not significantly higher than
controls, the observed dose-related increase seems to
suggest that the thyroid follicular cells are also the tar-
get in KBrO3 carcinogenesis. The slight differences in
resultsbetweenthetwostudies arepresumablybecause
ofvariation in animal lots and the numbers ofrats used.
The virtually safe dose (VSD) values calculated for
RCTs and DF on the basis of this experiment are dis-
cussed in the section "General Discussion and Sum-
mary."
Relationship between the Duration of Treatment
and the Incidence of RCTs in Rats ( 7). Subse-
quently, an experiment was designed to ascertain the
minimum induction time, minimum treatment period,
andtotal dosage ofKBrO3required forthe development
of RCTs (17). The dose of KBrO3 chosen for this study
was 500 ppm in the drinking water because significant
incidences of RCTs had already been observed at this
dose level. The experimental protocol using 232 male
F344 rats is illustrated in Figure 4.
CONTINUED-TREATMENT PROTOCOL (COMPARISON
BETWEENGROUPS 1 TO 5ANDGROUPS6 TO 10). Table8
shows the results of the histopathologic diagnosis of
Table 6. Incidences and average numbers of renal cell tumors (RCT) and dysplastic foci (DF) in male F344 rats
in the dose-response study.
Effective Number of rats (%) bearing Mean number of Number of Mean number
Group number of Adeno- RCT/cm2 rats (%) of DF/cm2
(dose, ppm) rats carcinoma Adenoma RCT of kidney ± SD with DF of kidney ± SD
500 20 3(15) 6(30)* 9(45)t 0.25 ± 0.35* 19(95)t 1.44 ± 1.10*
250 20 0 5(25)* 5(25)* 0.05 ± 0.088 19(95)t 0.83 ± 0.47*
125 24 0 5(21)* 5(21)* 0.04 ± 0.088 12(50)t 0.16 ± 0.20*
60 24 0 1(4) 1(4) 0.01 ± 0.04 6(25)* 0.07 ± 0.12*
30 20 0 0 0 0 5(25)* 0.05 ± 0.088
15a 19 0 0 0 0 1(5) 0.01 ± 0.04
0 19 0 0 0 0 0 0
aOne kidney lipoma was found in this group.
p < 0.05.
tp < 0.001.
tp < 0.001.
Sp < 0.05.
315KUROKAWA ETAL.
60
A
40
0
0
0. ,, 20* /
C
0
0 30 60 125 250 500
Doses of KBrO3 (PPm)
FIGURE 3. Dose-response curve for incidences of renal cell tumors
in male F344 rats.
tumors observed at relatively high incidence. DF and
renal adenomas were found as early as 26 weeks in the
administration period (group 7). The incidences of DF
and adenomas in rats treated with KBrO3 for 52 weeks
(group9) weresignificantlyhigherthanthoseincontrols
(group 4). When KBrO3 was given continuously for 104
weeks, renal adenocarcinomas and adenomas developed
in 3 and 6 of20 rats, respectively (group 10).
A few follicular adenomas of the thyroid were ob-
served in rats given KBrO3 (groups 7 to 9). The com-
bined incidences of follicular adenomas and adenocar-
cinomas of the thyroid were significantly increased in
rats treated continuously for 104 weeks (group 10). A
significant increase in the rate of peritoneal mesothe-
liomas was also found in the group continuously treated
for 104 weeks (group 10). Two mesotheliomas were ob-
served in rats exposed to KBrO3 for only 39 weeks.
LIMITED DURATION PROTOCOL (COMPARISON
BETWEEN GROUPS 5 OR 10 AND GROUPS 11 TO 14).
As shown in Table 8, RCTs were observed in rats ofall
groups receiving KBrO3 for limited durations (groups
11 to 14), the incidences all being significantly higher
than in controls and approximately equal to or slightly
higher than in rats given KBrO3 continuously for 104
weeks (group 10), probably because of the longer sur-
vival times in the former groups. On the other hand,
the mean numbers of DF or RCTs were increased in
relation to the length of exposure. The combined inci-
dences of follicular adenomas and adenocarcinomas of
the thyroid were significantly higher in rats in which
treatment was discontinued at 26 or 52 weeks (groups
12 and 14) when compared to control values (group 10).
Significant increases in the yield of peritoneal mesoth-
eliomas were also observed in all limited duration
groups.
The limited duration study thus revealed that the
yields of preneoplastic and neoplastic lesions remained
high, and therefore the effects of KBrO3 were not re-
versible. Furthermore, only 13 weeks of exposure was
necessary to produce increases in the incidences of
RCTs and mesotheliomas. Nonneoplastic changesinthe
kidney were not evident in limited duration groups,
demonstrating that toxic lesions, in contrast, do not
persist.
The mean total intake of KBrO3 in rats given a dose
of125 ppmfor 104 weeks (5.3g/kg)inthe dose-response
study was close to that of rats receiving a dose of 500
ppmforonly 13weeks (4.2-4.3g/kg)inthisstudy. How-
ever, the eventual incidence of RCTs was approxi-
mately 2-fold higher in the latter than in the former
group (50% vs. 21%). This phenomenon was also noted
in mice treated with 2-acetylaminofluorene (51,52). In
thisstudymuchhigherincidencesofbothliverandblad-
der tumors were observed in animals dosed for 9 or 12
months and sacrificed at 24 months than in groups re-
ceiving equivalent total doses spread over 18 or 24
months. Thus, higherdosesofKBrO3givenfor ashorter
period of time appear more effective for producing a
highyieldoftumors than alowerdose given for alonger
period.
It was concluded that the minimum induction time
for the development ofrenal adenomas was between 13
and 26 weeks, and the minimum treatment period and
Table 7. Incidences ofthyroid tumors and mesotheliomas in male F344 rats in the dose-response study.
Number (%) at doses of KBrO3, ppm
Categories 500 250 125 60 30 15 0
Number of rats at commencement 20 20 24 24 20 20 20
Effective number ofrats 20 20 24 24 20 20 19
Site and tumor type
Thyroid, number examineda 19 20 24 24 20 19 16
Follicular adenoma 5(26) 2(10) 0(0) 1(4) 0(0) 0(0) 0(0)
Follicular adenocarcinoma 2(11) 1(5) 0(0) 0(0) 0(0) 0(0) 0(0)
Follicular adenoma and adenocarcinoma combined 7(37)* 3(15) 0(0) 1(4) 0(0) 0(0) 0(0)
C-cell adenoma 1(5) 1(5) 0(0) 3(13) 5(25) 1(5) 2(13)
C-cell adenocarcinoma 0(0) 0(0) 1(4) 0(0) 0(0) 0(0) 1(6)
C-cell adenoma and adenocarcinoma combined 1(5) 1(5) 1(4) 3(13) 5(25) 1(5) 3(19)
Peritoneum, mesothelioma 15(75)t 3(15) 2(8) 4(17) 3(15) 0(0) 0(0)
aNumber ofrats for which thyroids were histologically examined.
*p < 0.05.
tp < 0.001.
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FIGURE 4. Experimental protocol for the continued and limited du-
ration protocol showing the duration ofadministration of DW and
KBrO3 solution.
total dose for the induction of renal adenomas and ad-
enocarcinomas were less than 13 weeks and less than 4
g/kg body weight, respectively, when the rats were
maintained thereafter on distilled water (DW) for 2
years. However, it is probable that the values for the
true minimum treatment period and total dose will be
smaller than 13 weeks and 4 g/kg body weight if ex-
periments involving shorter exposure to higher doses
of KBrO3 were performed.
Long-Term Observation ofRats after a Single IG
Administration. A total of 81 male F344 rats were
given a single IG administration of KBrO3 at doses of
600, 300, or 0 mg/kg and were observed for 87 weeks
(35). In the group administered 600 mg/kg, alarge renal
tumor developed that was diagnosed as an adenocar-
cinoma. Three renal adenomas were also found in the
same group. The final incidences of RCTs were 13.6%
(4/41), 0% (0/20), and 0% (0/20), respectively, in groups
given 600, 300, and 0 mg/kg. Considering the very low
spontaneous rate of RCT development in rats, it ap-
pears probable that KBrO3 exerted the initiation activ-
ity for induction ofthe lesions, despite the fact that the
incidence was not statistically significant.
Long-Term Oral Administration in Mice. A total
of 50 female B6C3F1 mice were given KBrO3 at doses
of 1000 or 500 ppm in the drinking water for 78 weeks,
and then tap water for 26 weeks until sacrifice at week
104 (15). Although body weight gain was markedly in-
hibited in the 1000-ppm group, the survival was com-
parable among groups. Daily intakes of KBrO3 were
119.8 and 56.5 mg/kg body weight/day in the animals
given 1000 and 500 ppm, respectively. Although rela-
tively high incidences of lung, liver, and lymph node
tumors were observed in the 1000-ppm group, the in-
cidences ofthesetumors were notsignificantly different
from those of the controls.
Afurtherstudywasconductedtoascertaintheeffects
of 750 ppm KBrO3 administered orally for 88 weeks to
groups of 27 male mice in B6C3F1, BDF1, and CDF1
strains (35). This study also resulted in no statistically
significant differences in growth rate or survival time
between the treated and control groups. The intake of
KBrO3 was in the range of60 to 90 mg/kg body weight/
day for all three strains.
As shown in Table 9, one renal adenocarcinoma was
found in a B6C3F1 mouse treated with KBrO3. Also, a
total offour renal adenomas developed in treated mice,
and DF were found in more treated mice than controls
ofboth B6C3F1 and BDF1 strains. There is a potential
forKBrO3to alsoinduce RTC inmice. Thisis attributed
to the fact that a) the spontaneous occurrence of RCT
in mice is very low [for example, in B6C3F1 mice the
incidences are reported to be 0.1% (3/2543) in males and
0.08% (2/2522) in females (53)], and b) the observed
RCTs were morphologically quite similar to those in-
duced by KBrO3 in rats. Furthermore, significant in-
creases in the occurrence of adenomas of the small in-
testine in CDF1 mice and of adenomas of the liver in
B6C3F1 were observed.
Long-Term Oral Administration in Hamsters.
Groups of 20 male Syrian golden hamsters were given
a KBrO3 supplement in their drinking water at concen-
trations of 2000, 500, 250, and 125 ppm for 89 weeks
(11).
No apparent differences were noted in the survival
times. The mean final body weights of animals treated
with 2000 ppm KBrO3 were significantly reduced, and
the mean absolute and relative kidney weights in ani-
mals given 2000 or 250 ppm KBrO3 were significantly
higher than controls. Renal adenomas developed in 1,
2, and 4 hamsters in groups given 250, 500, and 2000
ppm, respectively, foratotalincidence of7in 75treated
animals (9.3%). RCTs were not observed in controls,
and the structural and cellular morphologic character-
istics of RCT, as well as DF found in the exposed ham-
sters, were quite similar to those induced in rats. Be-
cause the spontaneousdevelopment ofRCTin hamsters
is known to be extremely low (55), it is highly likely
that the observed lesions, although of low incidence,
were induced by KBrO3.
Subcutaneous Injection into Newborn Mice and
Rats. KBrO3 was given at doses of 200, 100, 50, 25,
and 12.5 mg/kg body weight to newborn ICR mice and
at doses of 100, 50, 25, and 12.5 mg/kg body weight to
newborn F344 rats, either as single (24 hr after birth)
or 4 weekly SC injections until weanling (16). All the
survivingmice and rats were killed at weeks 78 and 82,
respectively.
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Table 8. Histopathologic diagnosis of tumors observed at relatively high incidence in male F344 rats given 500 ppm KBrO3 in the
drinking water for various periods.
Experimental group number
Treatment with KBrO3 (week)
Treatment with DW (week)
Number of rats at start
Number of rats effective
1 2
0 0
13 26
8 8
8 8
3 4 5
0 0 0
39 52 104
8 8 20
8 8 19
6
13
0
20
20
7 8
26 39
0 0
20 20
20 20
9 10 11 12 13 14
52 104 13 26 39 52
0 0 91 78 65 52
26 20 20 20 20 14
26 20 20 19 19 14
Site and number oftumors (%)
Kidney
Dysplastic foci (DF)
Adenoma
Adenocarcinoma
RCT
Mean number of DF/rat
Mean number ofrenal cell tumors/
rat
Thyroid
Follicular adenoma
Follicular adenocarcinoma
Follicular adenoma and
adenocarcinoma combined
C-cell adenoma
C-cell adenocarcinoma
C-cell adenoma and
adenocarcinoma combined
Peritoneum
Mesothelioma
*p < 0.01 (compared to group 4).
tp < 0.02.
tp < 0.001.
8p < 0.01.
0 0 0 0 0 0 1(5)
0 0 0 0 0 0 2(10)
0 000 0 0 0
0 0 0 0 0 0 2(10)
0 000 0 0 0.1
6(30)
3(15)
0
3(15)
0.4
16(62)*
15(58)*
0
15(58)*
1.8
19(95)j
6(30)t
3(15)
9(45)'
7.3
13(65)*
10(50)*
2(10)
10(50)*
1.2
17(89)'
9(47)'
1(5)
9(47)*
3.7
19(100)t
13(68)*
6(32)8
14(74)*
7.1
14(100)*
8(57)*
3(21)
9(64)*
11.5
0 0 0 0 0 0 0.05 0.10 0.81 1.25 0.55 0.65 1.26 0.93
0 0 0 0 0 0 1(5) 1(5) 2(8) 5(40)' 2(10) 3(16) 0 3(21)
0 0 0 0 0 0 0 0 0 2(10) 0 3(16) 1(5) 2(14)
0 0 0 00 0
0 0 0 0 2(11) 0
0 0 0 0 1(5) 0
0 0 0 0 3(16)0
1(5) 1(5) 2(8) 7(35)8
0 0 0 1(5)
0 0 0 0
0 0 0 1(5)
2(10)
0
1(5)
1(5)
0 0 0 0 0 0 0 2(10) 4(15) 15(75)* 6(30)"
6(32)8
0
0
0
1(5)
1(5)
0
1(5)
5(36)8
1(7)
0
1(5)
8(42)8 7(37)8 5(36)8
Table 9. Results of histopathologic diagnosis of lesions in three strains of male mice given 750 ppm KBrO3 orally.
Strain B6C3F1 BDF, CDF1
Treatment KBrO3 DW KBrO3 DW KBrO3 DW
Number of mice at start 27 15 27 15 27 15
Number of mice effective 26 15 27 15 27 15
Site and type of tumors
Kidney
Adenocarcinoma 1 0 0 0 0 0
Adenoma 2 0 1 0 1 0
RCT 3 0 1 0 1 0
Dysplastic foci 2 1 4 1 0 0
Small intestine
Adenocarcinoma 1 0 0 0 0 0
Adenoma 1 1 0 1 14* 1
Liver
Adenocarcinoma 6 3 1 2 0 2
Adenoma 7t 0 3 1 0 1
Hemangioma 1 0 0 0 0 0
p < 0.01.
tp < 0.05.
Histologically, no nonneoplastic or neoplastic lesions
ofthe skin were observed atthe injection sites in either
species. While no RCTs were observed, the numbers
of animals bearing DF were high in both treated and
control groups, with the frequency of lesions being in
the range of 1.5 to 6.0 (mean 3.4) per mouse. Only a
few tumorous lesions of the kidney were observed in
the rats. Therefore, it was concluded that KBrO3 does
not exert any potent carcinogenic action for local or
distant organs when administered SC to newborn mice
and rats for 4 weeks at doses up to 200 (rats) or 100
(mice) mg/kg body weight.
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Pathological Lesions of the Kidney
after KBrO3 Administration
Neoplastic and Preneoplastic Changes
Renal CeU Tumors. Recent studies on the histo-
genesis of renal adenocarcinomas induced by chemical
carcinogens in rats have revealed that adenomas grad-
ually progress toadenocarcinomasandthathyperplastic
tubular epithelium constitutes the preneoplastic lesion
(6). However, there is still some controversy as to the
best nomenclature for differential diagnosis ofrenal ad-
enomas and adenocarcinomas in experimental animals
and man. Therefore, the incidences ofadenocarcinomas
and adenomas were combined as RCTs for evaluation
of the carcinogenic and promoting activities of KBrO3
in all of our studies. In this chapter, however, the def-
inition and histopathologic features of renal adenomas
and adenocarcinomas induced by KBrO3 are separately
described.
Macroscopically, some tumors were observed as
round yellowish-white or grayish-white projections of
the renal cortex, clearly distinguishable from the sur-
rounding tissues. However, most tumors grossly ap-
peared as small yellowish-white nodules on cut surfaces
or were only detectable by microscopic examination
after long-term treatment with KBrO3. The majority of
lesions closely resembled one anotherin theirhistologic
appearance.
Adenomas appeared as oval, solitary nodules con-
sistingofcloselypackedpolygonalcellsand werelocated
in the cortical area. They were well circumscribed with
thin, fibrous capsules or pseudocapsules ofcompressed
neighboring tissues. Although most tumors demon-
strated asolid growth pattern, somepresented as cystic
structures with papillary projections protruding into
the lumen. The tumor cells were shown to have clear
cytoplasm (clear cell), eosinophilic granular cytoplasm
(granular cell), or homogeneously basophilic cytoplasm
(dark cell). There was no nuclear pleomorphism and
mitotic figures were rare (Figs. 5-7).
FIGURE 5. Solid adenoma filled with eosinophilic material.
FIGURE 6. Solid adenoma composed ofclear, polygonal cells.
FIGURE 7. Cystic adenomawithpapillaryprojectionprotrudinginto
the lumen.
Adenocarcinomas were usually irregularly contoured
as if two or more small nodules became aggregated.
Thesetumorsweremostlylocalizedinthecorticalareas,
although occasionally they exhibited a deep downward
growthfromthecortexintothemedulla. Mostexhibited
a solid growth pattern, but in some cases, they showed
trabecular, tubular, or papillary patterns (Figs. 8 and
9). In some large adenocarcinomas, extensive areas of
necrosis andhemorrhagewereobserved. Themalignant
tumor cells-like those in adenomas-were also polyg-
onalin shape and demonstrated clear, granular, ordark
cytoplasm. Mitotic figures were occasionally seen but
nuclear pleomorphism was not apparent (Fig. 10). Ap-
parent infiltrative growth was observed in cases of
grossly large tumors. A lung metastasis was found in
one case in the rat carcinogenicity test.
Essentially, the histologic features of RCTs found in
KBrO3-treatedmalehamstersandmalemicewerequite
similar to those observed in KBrO3-treated rats.
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FIGURE 9. An adenocarcinoma composed of multiple small nodules FIGURE 8. Large adenocarcinoma demonstrating tubular struc- extending into the medulla.
FIGURE 10. Adenocarcinoma consisting of granular cells; nuclear
pleomorphism is not evident.
Dysplastic Foci. Focal tubular lesions that showed
hyperplasia ofthetubularliningepithelium, whichoften
resulted in narrowing of the tubular lumina, were di-
agnosed as dysplastic foci (DF) throughout our studies
(Fig. 11). Dilated tubules with multilayered and/or en-
larged epithelial cells with a papillary growth pattern
were also classified as DF (Fig. 12).
DF in our study seem to correspond to putative pre-
neoplastic lesions described by others as atypical cell
foci, pathologically changed tubules, focal areas ofdys-
plastic tubular epithelium, small nodules, or dysplasia
(8).
Nonneoplastic Changes
Renal tubules in KBrO3-treated rats demonstrated
various degenerative, necrotic, and regenerative
changes. Numerous eosinophilic bodies were observed
FIGURE 11. Dilated tubular lesion demonstrating hyperplastic epi-
thelium.
in the cytoplasm of proximal renal tubules in rats
treated continuously with KBrO3 for 13 to 104 weeks.
However, these changes were not evident inrats ofthe
limited duration experiment, indicating that they are
reversible. Hyaline casts in the tubular lumen, hyaline
droplets, and brown pigments in the tubularepithelium
were also commonly observed. Although these lesions
were also found in control rats, they were more exten-
sive in both degree and distribution in treated rats,
especially in males. Vascular changes, which were ob-
served in the rat study after feeding KBrO3-treated
bread (49), were not evident in any organs.
Thetransitional epitheliumoftherenalpelvis showed
thickening, papillary hyperplasia, and growth, espe-
cially in treated males. Calcium deposits in the renal
pelvis were also marked in rats showing the hyper-
plastic changes.
These nonneoplastic changes occurred to a lesser de-
gree in hamsters and mice given KBrO3 than in rats.
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FIGURE 12. Focal lesion demonstrating multilayering ofthe tubular
epithelium.
Initiation and Promotion
Assay for Promoting Potential for Kidney,
Liver, and Urinary Bladder Tumorigenesis
in the Rat
Although the carcinogenicity of KBrO3 in rats was
definitely established by several experiments, it was
thought necessary to test the promoting effects ofthis
compound to better understand the mechanisms under-
lying its carcinogenic action and organ specificity (5).
N-Ethyl-N-hydroxyethylnitrosamine (EHEN) was
used as an initiator for this purpose because this car-
cinogen is known as a potent initiator useful for deter-
mining the promotion potential ofexogenous chemicals
on kidney and liver tumorigenesis (56-58).
Atotalof128maleF344ratsweregivenEHENorally
for 2 weeks and then 500 ppm KBrO3 orally for the
following 24 weeks. The kidney and liver were cut into
6 to 8 serial slices. The numbers of microscopic neo-
plastic lesions were counted, and the entire areas ofthe
sections were measured with a semiautomatic image
analyzer (TAS-plus, Leitz Wetzlar, West Germany).
Therewere significantly increased incidences ofDF and
average numbers of both DF and RCT/cm2 in groups
given KBrO3 after initiation as compared to values for
animalstreatedwith EHEN alone;thereforethesefind-
ings clearly demonstrated enhancing activity ofKBrO3
on kidney lesion development (Table 10). No hyper-
plastic orneoplastic changes were observed inthe renal
pelvis or urinary bladder in any ofthe groups, and no
significant differences in the incidences and average
numbers of hyperplastic foci, neoplastic nodules, and
hepatocellular carcinomas were found.
Recently, a very effective rapid bioassay system for
rat hepatocarcinogenesis was developed, based on the
two-stage carcinogenesis concept (59). In this model
rats were given a single dose (200 mg/kg) of diethyl-
nitrosamine IP as an initiator and then fed KBrO3 in
the diet (4000 ppm) for 6 weeks. A two-thirds partial
hepatectomy was performed at week 3. As in the long-
term experiment, KBrO3 showed no enhancing effect
on hepatocarcinogenesis.
Dose-Response Studies on the Promoting
Potential for Renal Tumorigenesis in the
Rat
Dose-response studies using a total of 180 male F344
rats were undertaken to clarify whether a threshold
level of KBrO3 treatment exists for promotion ofrenal
tumorigenesis (8). ThepromotingeffectofKBrwas also
tested since KBrO3 is easily degraded to KBr during
the baking process. Experimental protocols were sim-
ilar to those used in the previous promotion study (5).
The mean numbers of DF/cm2 were found to be sig-
nificantly increased in a dose-related manner in rats
treated with > 30 ppm KBrO3 (Table 11). A parabolic
curve was obtained by exponential regression analysis
when the numbers of DF/cm2 were plotted against the
Table 10. Incidences and average numbers of dysplastic foci (DF) and renal cell tumors (RCT) in male F344 rats treated with EHEN
and KBrO3.
Experimental
group number Treatment, ppm
1 DW
2 EHEN (1000) + DW
3 EHEN (500) + DW
4 EHEN (1000) + KBrO3 (500)
5 EHEN (500) + KBrO3 (500)
6 KBrO3 (500)
ap < 0.01 (compared with group 2). bp < 0.05.
Cp < 0.01.
dp < 0.05 (compared with group 3).
Effective
number of
rats
19
22
23
19
20
20
Number of
rats with
DF(%)
2(11)
17(77)
15(65)
19(100)
19(95)b
7(35)
Average number
of DF/cm2
0.02 ± 0.05
0.39 + 0.37
0.20 ± 0.20
1.11 ± 0.45k
0.98 ± 0.38c
0.07 ± 0.10
Number of
rats with
RCT (%)
0(0)
9(41)
4(17)
9(47)
10(50)
0(0)
Average number
of RCT/cm2
0.00
0.08 ± 0.12
0.03 ± 0.06
0.11 ± 0.14
0.13 ± 0.16d
0.00
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Table 11. Incidences and average numbers of dysplastic foci (DF) and renal cell tumors (RCT) in male F344 rats treated with hBrO3
or KBr at various doses after initiation with EHEN at a dose of 500 ppm orally.
Experimental Effective Number of rats with Average number of Number of rats with
group number Treatment, ppm number of rats DF (%) DF/cm2 ±- SD RCT(%
1 DW + DW 15 0(0) 0.00 0(0)
2 DW + KBrO3 (500) 15 0(0) 0.00 0(0)
3 DW + KBr(1750) 14 0(0) 0.00 0(0)
4 EHEN + DW 15 12(80) 0.29 ± 0.16 3(20)
S EHEN + KBrO3(15) 14 11(79) 0.39 ± 0.19 4(27)
6 EHEN + KBrO3(30) 15 14(93) 0.49 ± 0.30b 4(27)
7 EHEN + KBrO3(60) 15 14(93) 0.61 ± 0.29a 3(20)
8 EHEN + KBrO3(125) 15 15(100) 0.79 ± 0.33a 6(40)
9 EHEN + KBrO3(250) 15 15(100) 1.22 ± 0.56a 5(33)
10 EHEN + KBrO3(500) 15 15(100) 1.25 ± 0.76a 8(53)
11 EHEN + KBr(350) 15 8(53) 0.15 ± 0.16 3(20)
12 EHEN + KBr(1750) 15 8(53) 0.16 ± 0.20 5(33)
ap <0.01.
bp < 0.05 (from group 4).
0 60 125 250
simple regression
anaiysis
exponentiai regression
analysis
Dose of KBrO3 (ppm)
FIGURE 13. Dose-response curve for DF/cm2 in rats treated with KBrO3 after EHEN initiation.
dose of KBrO3 (Fig. 13). No promoting effect was ob-
served with KBr.
Thus, the threshold level of KBrO3 in the drinking
water for promotion of renal tumorigenesis seems to lie
between 15 and 30 ppm. In view of the lack of dose-
dependent increases in the mean size and areas of RCT
per kidney and the fact that lesion morphology and
growth rate appeared unaffected, it is probable that
KBrO3 exerted its promoting effect by directly altering
expression of other characters in the initiated cell pop-
ulation.
Assay of Two-Stage and Complete
Carcinogenesis in Mouse Skin
Since KBrO3 has been used as a neutralizer in per-
manent wave preparations that have contact with the
skin (27), studies on the promoting or complete carcin-
ogenic potential of direct application of KBrO3 to this
tissue were considered of interest (7).
In the experiment to determine promoting activity,
groups of 20 female Sencar mice received a single topical
application of DMBA (20 nmole) followed by treatment
with KBrO3 (40 mglmL), 12-O-tetradecanoylphorbol-13-
acetate (TPA) (10 Rg/mL), or the acetone solvent alone
for 51 weeks. To test for complete carcinogenic activity,
groups of 20 mice were also given KBrO3 (40 mg/mL)
without prior initiation. Histopathological examination
did not reveal any epidermal hyperplasias, squamous
cell papillomas, or squamous cell carcinomas in mice
treated with KBrO3 from either the promotion or com-
plete carcinogenesis studies. In complete contrast, a
strong promoting action was evident in positive control
mice administered TPA.
Two-Stage Whole Body Carcinogenesis in
the Rat
Methylnitrosourea (MNU) has been shown to be use-
ful as an initiator to detect the promoting potential of
2.0 -
z
0
0
C,
1.51-
1.0 -
0.5 -
0
322TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE
chemicals fortumors ofthe nervous, hematopoietic, and
GI tract systems; and thyroid, liver, and urinary blad-
der (60). The MNU two-stage carcinogenesis model was
applied to ascertain whether KBrO3 may act as a pro-
moter in organs other than the kidney (Kurokawa, un-
published data). Groupsof20male F344rats weregiven
4 IP injections of MNU at doses of 40, 20, and 10 mg/
kgbodywt. for2weeks, and then given 500ppm KBrO3
orally in the drinking water for 24 weeks. Although
relatively high incidences ofmesotheliomas, leukemias,
and tumors ofthe tongue, forestomach, small intestine,
and lung were observed, no significant promoting ef-
fects of KBrO3 on development of these tumors were
evident.
Assay of Two-Stage Forestomach
Carcinogenesis in Mice
Groups of 12 male C57BL mice received a single IG
administration of dimethylbenzanthracene (DMBA, 25
or 50 mg/kg) as the initiation step and were then ad-
ministered 500 ppm KBrO3 orally for 26 weeks (Kuro-
kawa, unpublished data). No increases in the incidences
of either papillomas or hyperplasias in the forestomach
epithelium of mice were observed, KBrO3-treated as
opposed to control mice. No positive controls were used
in this study.
Assay of Two-Stage Esophageal
Carcinogenesis in the Rat
Groups of 15 male F344 rats were given dibutylni-
trosamine (DBN) at adose of500ppmorallyfor4weeks
as the initiation step and then administered 500 ppm
KBrO3 orally for 32 weeks (Kurokawa, unpublished
data). The incidences ofneoplastic lesions ofthe esoph-
agus and other GI tract organs in rats given KBrO3
after initiation were not significantly increased as com-
pared to control values.
Mutagenicity
Microbial Assays
In Japan microbial testing of KBrO3 was conducted
simultaneously in several laboratories under the coop-
erative program on short-term assays (2). Using Sal-
monella typhimurium TA100, KBrO3 was found to be
weakly positive at a concentration of 3 mg/plate after
metabolic activation. However, the compound proved
negative in TA98, TA1535, TA1537, TA1538, E. coli
WP2try- andE. coliWP2try-his- withorwithoutmet-
abolic activation (2,61,62). Similarly, inthe USAno mu-
tagenic activity could be demonstrated for KBrO3 in
Salmonella typhimurium (strains not specified) orSar-
cina cerevisiae (Litton Bionetics, personal communi-
cation).
Very recently, microbial tests were reconducted in
our laboratory (Kurokawa, unpublished data). Weak
mutagenic activities were again demonstrated in TA100
at doses of 2 to 4 mg/plate with or without metabolic
activation. KBrO3 was also mutagenic in TA102 and
TA104, strains which are sensitive to chemicals that
generate active oxygen radicals (63) in the presence of
metabolic activation (Fig. 14). KBrwasnegativeinboth
TA98 and TA100.
Microbial assays of NaBrO3 and silver bromate
(AgBrO3) were also conducted in strains TA 97, 98, 100,
and 102 in order to ascertain the general mutagenic
potential ofbromate (BrOi3) compounds. Both NaBrO3
and AgBrO3 proved negative in all strains tested at the
maximum levels of 5 mg/plate and 25 ,ug/plate, respec-
tively (Kurokawa, unpublished data). The very low sol-
ubilityofAgBrO3mightbethereasonfornegativedata.
The results of Rec assays on KBrO3 using Bacillus
subtilis (17Arec+, 45Trec+) were also negative with or
without metabolic activation (2).
Chromosome Aberration Tests
Therates ofchromosome aberrations in Chinese ham-
ster lung (CHL) cells treated with KBrO3 were found
to be significantly higherthan in controls at dose ranges
of 0.0625 to 0.25 mg/mL, in a dose-dependent manner,
without metabolic activation (2,64-66) (Table 12).
Mainly chromatid type breaks and exchanges were in-
duced. The value D20, representing the dose at which
aberrations were detected in 20% of metaphase cells,
was calculated to be 0.071 mg/mL. Therefore, the clas-
togenic activity of KBrO3 was considered to be rela-
tively strong (66).
Chromatid breaks were also induced in cultured
Chinese hamster DON-6 cells by the addition of 5 x
10-4 M (0.0835 mg/mL) KBrO3 (67). In vivo clastogenic
activityofKBrO3was furtherexamined inbone marrow
cells of male Long-Evans rats administered KBrO3 by
IP and oral routes. The incidences of aberrant meta-
phase cellswere significantly increased, reachingamax-
imum of 10.5% at 18 hr (IP, 250.5 mg/kg body weight)
and of 10.8% at 18 hr (oral, 334.0 mg/kg body weight).
On the contrary, an IP injection ofheat treated KBrO3
(190°C or 230°C for 20 min) at a dose of 167 mg/kg body
weight had no effect on numbers of aberrant cells (68).
KBr was positive in the chromosome aberration test
at doses greater than 4 mg/mL, inducing chromatid
gaps, breaks, and exchanges (62,66). However the D20
of KBr (3.7 mg/mL) was much higher than that of
KBrO3.
Micronucleus Tests
Micronucleated polychromatic erythrocytes were in-
duced in male ddY mice in a dose-dependent manner
when KBrO3 was administered at doses higher than 25
and 100 mg/kg body weight by IP and oral routes, re-
spectively (69). Among 47 compounds tested, including
39 synthetic and naturalfood additives, onlyKBrO3was
positive by both IP and oral application. In contrast,
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FIGURE 14. Microbial assays of KBrO3 using five strains ofSalmonella typhimurium. *Previous test in 1976; others are data in 1987.
Table 12. Chromosome aberration test on KBrO3 and KBr.
Cells with structural
Treatment Concentration, chromosomal
time, hr mg/mL aberrations, % Judge
KBrO3 24 0 4
24 0.0625 10 +
24 0.125 27 +
24 0.25 100 +
48 0.0625 10 +
48 0.125 26 +
48 0.25 Toxic Toxic
KBr 24 0 4
24 2.0 4 -
24 4.0 10 +
24 6.0 39 +
48 2.0 3 -
48 4.0 12 +
48 6.0 76 +
KBr was negative after up to five IP injections at doses
inthe range of62.5 to 500mg/kgbodyweight. Induction
of micronuclei by KBrO3 was compared in male ddY
mice and a mutagen-sensitive mouse strain (designated
as MS) after asingle IP administration (70), andpositive
results were obtained in both; a higher susceptibility of
the sensitive strain to KBrO3 was also confirmed. No
sex differences were evident in ddY mice for the in-
duction ofmicronuclei byKBrO3 after asingle IP admin-
istration (71).
Silk Worm Test
Mutagenicity testing using silk worms was reported
to be negative (2).
Absorption, Distribution, Excretion
and Metabolism
In Vivo Studies
Male Wistar rats were given KBrO3 IG at a dose of
50 mg/kg body weight as BrO3, and the levels ofBrO3
and Br- in various organs were examined (72). Each
organ was homogenized in water and freeze-dried and
then assayed using ion chromatography method (28).
As shown in Table 13, approximately 30% ofBrO3was
detected in the urine 24 hr after the treatment. The
levels ofBr- were increased significantly in the plasma,
RBC, kidney, pancreas, stomach, small intestine, and
urine. Thus it is evident that the BrO3given orally was
absorbed and partly excreted, unchanged in the urine;
the remainder was at leastpartly reduced to Br-. How-
ever, it was not clear whether the increased Br- all
originated via degradation of BrO3 or if redistribution
in the body might play a role. Also it is unknown
whetherBrO3 or Br- was nottotally extracted because
ofbindingwithinsoluble fractions, proteins, etc., during
sample preparation or for other reasons. Clarification
of these points will require further study including the
development of a microassay for biological specimens.
Time-related changes in the levels of BrO3 after the
IG administration of KBrO3 (100 mg/kg body weight)
are illustrated in Figures 15 and 16. It is evident that
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Table 13. BrO; and Br- levels in tissues and feces 24 hr after IG administration of KBrO3 to male Wistar rats.
BrO; Br-
Samplesa Control KBrO3-treated Control KBrO3-treated
Plasma NDb ND 51.4 ± 0.9 187.1 ± 0.3*
RBC ND ND 47.2 ± 2.0 289.0 ± 1.0*
Spleen ND ND 51.3 ± 22.1 102.1 ± 13.9
Kidney ND ND 12.7 ± 1.7 87.4 ± 4.6*
Liver ND ND 30.6 ± 1.2 42.6 ± 7.1
Pancreas ND ND 13.6 ± 1.8 32.1 ± 3.3*
Stomach ND ND 36.1 ± 4.6 113.5 ± 14.1*
Small intestine ND ND 34.6 ± 0.1 62.5 ± 3.5*
Urine ND 1729.9 ± 11.4* 212.6 ± 6.5 1314.1 ± 4.1*
Feces ND 14.1 ± 0.3* 13.0 ± 0.3 12.3 ± 0.3
aUnits in plasma, RBC, tissues = micrograms per gram; in urine, feces = micrograms per 24 hr.
bND = < 2.5 p.g/mL (urine, plasma), < 5,g/g (tissues).
*p < 0.01 as compared to control (mean ± SD).
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FIGURE 16. Levels of BrO3- in plasma and urine after IG admin-
istration of KBrO3.
FIGURE 15. Levels ofBrO3 in stomach and smallintestine contents
after IG administration of KBrO3.
BrO3 was rapidly absorbed and degraded in the stom-
ach, small intestine, plasma, and urine within 2 to 4 hr.
Dose-response studies further revealed that no BrO3
was detectable inthe urineofratsgiven KBrO3 atdoses
lower than 2.5 mg/kg body weight. However, at doses
higher than 5 mg/kg body weight, a dose-related in-
crease in the levels ofBrO3 excreted into the urine was
apparent (Fig. 17). Therefore, it is probable that BrO3
could have exerted direct effects on the renal tubular
epithelial cells at doseshigherthan 5mg/kg; thisfinding
could help to explain the mechanism of carcinogenicity
ofthis compound in the kidney.
In Vitro Studies
The decomposition ofBrO3 in various rat tissues was
examined in vitro to cast light on the mechanism of in
vivo biodegradation (73).
As shown in Table 14, no degradative activity was
3 60 D0 100
dose of BrO3 (mglkg)
FIGURE 17. Changes in the levels of urinary excretion of BrO3-
after IG administration of KBrO3.
observed with human saliva. On the other hand, rat
liverandkidneyhomogenates and RBCs showed strong
activity for biodegradation of BrO3 when incubated at
37°C for 3 min. The activities still remained at the same
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Table 14. Degradation of BrO3 in vitro by human saliva and rat tissue homogenates.
BrO3, ppm, BrO3, ppm, Recovery,
before incubation after incubationa %
Saline 10 6.96 ± 0.40 100.0
Saliva 10 6.25 ± 0.40 89.9
Saline 5 4.30 ± 0.60 100.0
Liver 5 Not discernable 0
(0.03 ± 0.07) (Trace)
Kidney 5 0.03 ± 0.04 Trace
(0.07 + 0.03) (Trace)
Spleen 5 0.46 ± 0.22 10.7
Stomach 5 1.30 ± 0.17 30.2
Small intestine 5 0.42 ± 0.05 9.8
Plasma 5 3.68 + 0.18 85.6
(4.20 ± 0.52) (97.7)
RBC 5 0.02 ± 0.02 Trace
(0.94 ± 0.08) (21.9)
Gastric juice 5 0.79 ± 0.12 18.4
aConcentration of BrO3 after incumbation with heat treated homogenate, plasma or hemolysate (100°C, 5 min); mean ± SD of three
experiments. Incubation at 37°C, 3 min.
levels after heat treatment at 100°C for 5 min. Subse-
quently, supernatants from tissues showing degrada-
tive activity were fractionated by gel filtration. High
and low molecular weight liver fractions-the latter
containing GSH and other -SH compounds-were ex-
amined. The activity of the former disappeared after
heating, whereas that ofthe latterwas retained. Hemo-
lyzed RBCs, kidney, small intestinal mucosa, and stom-
ach tissues could be also fractionated togive two similar
components.
SH compounds such as cysteine, glutathione (GSH),
and ergothioneine were found to have BrO3 degrada-
tive activity (Table 15) and simultaneous analysis of
residual BrO-3 and yielded Br- in the presence ofGSH
revealed a near stoichiometric response, as shown in
Figure 18. From these data it is highly probable that
GSH is intimately involved in the degradation ofBrO3.
Moreover, Br- is yielded in the GSH-mediated reaction
that corresponds well to the factthat Br- concentration
increased in organs andurine ofrats afteranoraladmin-
istration of BrO3.
Studies on the Mechanism of KBrO3
Carcinogenesis
Toxicological Studies
Lipid peroxide (LPO) in tissues is mainly generated
by the oxidative deterioration of cell membrane poly-
unsaturated fatty acids by active oxygen species (74).
Table 15. Degradation of BrO-3 by SH compo.unds in vitro.'
Concentration of BrO3, ppm
5 10 20
Cysteine 0 13.0 47.0
Glutathione 0 0.9 47.5
Ergothioneine 20.9 35.2 59.5
aNumbers denote percent of initial concentration after incubation
at 37°C for 30 min with 0.1 mM of each SH compound.
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Stoichiometric degradation of BrO3- to Br- by gluta-
The protective role of cysteine and GSH and the dele-
terious influence of diethylmaleate (DEM), a GSH-de-
pleter, on cellularoxidative damage and LPO formation
are well known (75).
LipidPeroxidation in the Kidney. Changes in the
levels of LPO in the kidney of male F344 rats, CDF1,
BDF1, and B6C3F1 mice, and Syrian golden hamsters
were studied after IV administration of KBrO3. Alter-
ation in levels of malondialdehyde (MDA, nmole/g wet
tissue) was used as an index of LPO according to the
procedure using thiobarbituric acid (TBA) (76). The
TBAmethodhasbeenusedextensivelytomeasure LPO
levels in the liver, and its recent application to the kid-
ney allowed dose-dependent and time-dependent
changestobe showninresponsetoexogenous chemicals
(77-79).
As illustrated in Figure 19, LPO levels were signif-
icantly increased in rats given KBrO3 without them re-
ceiving accompanying cysteine treatment. However,
when the rats were also given IP injections ofcysteine
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FIGURE 19. Levels of LPO in the kidneys of male F344 rats 24 hr
after a single IV administration of KBrO3 at doses of 77, 96, 120,
or 150 mg/kg with or without cysteine treatment. Each bar rep-
resents the mean + SD offour rats. **p < 0.01 and *p < 0.05 as
compared to controls.
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FIGURE 20. Changes in the levels of LPO in the kidneys of male
F344 rats at 2, 4, 6, 12, 24, and 48 hr after a single IV adminis-
tration of 120 mg/kg of KBrO3. The levels of LPO are expressed
as ratios to concurrent control values sacrificed at the same ex-
perimental time points. Each point represents the mean ± SD of
five rats. **p < 0.01 and *p < 0.05 as compared to controls.
(400 mg/kg) 30 min before and after IV treatment with
KBrO3, this change was inhibited. In contrast, when
DEM (0.7 mL/kg) was administered IP 1 hr before IV
treatment by KBrO3 (20 mg/kg), LPO levels were sig-
nificantly elevated (KBrO3 alone; 214.6 + 15.6 versus
DEM + KBrO3; 347.7 ± 64.9, p < 0.05). Figure 20
shows the time-dependence of LPO elevation in rats
receiving a single KBrO3 treatment of 120 mg/kg body
weight. After an initial significant decrease at 6 hr, the
levels of LPO were found to be significantly increased
at 12, 24, and 48hr. However, LPO levels inthe kidneys
of mice and hamsters did not demonstrate any equiv-
alent increase at this dose level of KBrO3.
Therefore, dose- and time-related significant in-
creases in the levels of LPO were apparent in the kid-
neys of male rats given KBrO3 at a dose of 77 mg/kg
bodyweight orabove. These overall datastrongly show
a particularly strong potential for oxidative damage in
the kidney of rats; this finding might explain the ob-
served species differences in susceptibility to KBrO3
carcinogenicity to the kidney.
Effects ofGSH, Cysteine, and DEM Treatment on
Mortality. InratsgivenKBrO3 IVwithoutGSHtreat-
ment, all animals died within 3 days at a dose as low as
108 mg/kg (18). On the other hand, when animals were
also treated with GSH, mortality was greatly reduced
and no animals died at doses lower than 214 mg/kg
KBrO3 (Table 16). Similar results were observed with
cysteine treatment (Table 17), and-again in con-
trast-when rats were pretreated with DEM (Table
18), mortality was significantly increased.
Changes in Serum Biochemistry. As shown in Ta-
ble 19, the levels of NPN, BUN, and creatinine were
significantly increased in a dose-related manner in male
F344 rats after a single IV administration of KBrO3
(18). Elevation was first observed between 3 and 6 hr,
peaking at 24 hr before returning to normal at 48 hr
(Table 20). However, the increase in values for these
parameters was significantly inhibited in rats treated
with GSH or cysteine (Table 21). DEM treatment had
the opposite effect, bringing about a significant further
elevation over KBrO3-alone levels (Table 22).
Table 16. Effect of glutathione (GSH) treatment on mortality of
male F344 rats given IV injection of KBrO3.
Doses of KBrO,, Number of animals dead (days)a
mg/kg GSH-treatedb Saline-treatedb
300 8 (2) 8 (1)
268 6 (3) 8 (1)
239 2 (2)* 8 (1)
214 ot 8 (1)
170 Ot 8 (1)
136 ot 8 (2)
108 ot 8 (3)
86 0 0
aEight animals were used for each group and observed for 14 days.
bGSH (800mg/kg) or saline was injected IP 30 minbefore and after
KBrO3 administration.
*p < 0.01.
tp < 0.001 compared to saline-treated controls.
Table 17. Effect of cysteine treatment on mortality of male F344
rats given IV injection of KBrO3.
Doses of KBrO, Number of animals dead (days)a
mg/kg Cysteine-treatedb Saline-treatedb
169 0 5 (1-2)
130 0 5 (2)
100 0 0
77 0 0
aFive animals were used for each group and observed for 7 days.
bCysteine (400 mg/kg) or saline was injected IP 30 min before and
after KBrO3 administration.
*p < 0.01 compared to saline-treated controls.
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Table 18. Effect of diethyl maleate (DEM) treatment on
mortality in male F344 rats given IV injection of KBrO3.
Doses of KBrO3, Number of animals dead (days)a
mg/kg DEM-treatedb Saline-treatedb
49 4 (1-2)* 0
29 4 (1-2)* 0
17 0 0
10 0 0
aFive animals were used for each group and observed for 7 days.
bDEM (0.7 mL/kg) or saline was injected IP 60 min before KBrO3
administration.
p < 0.05 compared to saline-treated controls.
Table 19. Dose-response studies of serum biochemistry in male
F344 rats given a single IV injection of KBrO3.
Doses of KBrO3, NPN, BUN, Creatinine,
mg/kg mg/dL + SD mg/dL ± SD mg/dL ± SD
0 30.8 + 2.2 14.6 + 1.3 0.3 ± 0.1
77 79.1 ± 11.4* 52.9 + 8.4* 0.5 ± 0.1'
96 182.0 ± 45.7* 154.6 ± 32.2§ 2.0 ± 0.5*
120 231.5 ± 11.1* 194.7 ± 7.2* 2.8 ± 0.3*
150 264.0 ± 17.6t 221.3 ± 20.2t 4.0 ± 0.6k
aThree rats per dose were sacrificed 24 hr after IV injection of
KBrO3.
tp < 0.01.
*p < 0.001.
tp < 0.05.
§p < 0.02 compared to saline-treated controls.
Table 20. Time course studies of serum biochemistry in male
F344 rats given a single IV injection of KBrO3a
Time after
KBrO3, NPN, BUN, Creatinine,
injection, hra mg/dL + SD mg/dL ± SD mg/dL ± SD
0 33.7 ± 5.1 15.6 ± 1.9 0.3 ± 0.0
1 30.9 ± 1.6 15.0 ± 1.0 0.4 ± 0.1
3 35.7 ± 1.2 19.7 + 1.3* 0.5 ± 0.1*
6 58.4 ± 5.8* 35.9 ± 6.9* 0.5 ± 0.1*
12 79.5 ± 4.3' 51.1 ± 3.0t 0.5 ± 0.1'
24 210.7 ± 12.0t 169.6 ± 6.4t 2.3 ± 0.2*
48 37.5 ± 0.5 17.2 ± 1.4 0.4 ± 0.1
aThree ratswere sacrificed sequentially after IVinjectionofKBrO3
(120 mg/kg).
*p < 0.01.
tp < 0.001.
tp < 0.05 compared to saline-trated controls.
Formation of 8-Hydroxydeoxyguanosine
(8-OH-dG) in Rat Kidney DNA
8-OH-dG is one of the DNA-damaged products
formed in vitro and in vivo by oxygen radical-forming
agents, such as reducing agents, asbestos-H202, poly-
phenol-Fe3" -H202 and radiation (80-82). It was there-
fore considered ofinterest to determine therelationship
between 8-OH-dG formation in tissue DNA and the car-
cinogenicpotentialofanoxidizingagentlikeKBrO3(19).
As shown in Figure 21, the 8-OH-dG in kidney DNA
of male F344 rats increased 4-fold up to 6 residues/105
deoxyguanosine (dG), 24 hr after a single IG KBrO3
administration. After 48 hr, a slight reduction towards
Table 21. Effect of GSH or cysteine treatment on serum
biochemistry in male F344 rats given a single IV injection
of KBrO3.0
NPN, BUN, Creatinine,
Treatment mg/dL ± SD mg/dL ± SD mg/dL ± SD
Saline 28.1 ± 0.8 16.0 ± 1.5 0.3 ± 0.1
KBrO3 193.8 ± 18.6* 177.5 ± 9.2t 2.5 ± 0.lt
KBrO3 + GSH 81.8 ± 38.3# 67.9 ± 40.5* 0.9 ± 0.4"1
KBrO3 + cysteine 33.4 ± 11.90 18.3 + 6.2§ 0.4 ± 0.0§
aThree rats per dose were sacrificed 24 hr after IV injection of
KBrO3 (120 mg/kg). GSH (800 mg/kg) or cysteine (400 mg/kg) were
injected IP 30 min before and after KBrO3 administration.
*p < 0.01.
tp < 0.001.
tp < 0.05 compared to saline-treated controls.
§P < 0.001.
"lp < 0.01.
#p < 0.05 compared to KBrO3-treated controls.
Table 22. Effect of DEM treatment on serum biochemistry in
male F344 rats given a single IV injection of KBrO3.8
NPN, BUN, Creatinine,
Treatment mg/dL ± SD mg/dL ± SD mg/dL ± SD
Saline 28.1 ± 0.8 16.0 ± 1.5 0.3 ± 0.1
KBrO3 28.6 ± 2.3 15.9 ± 1.6 0.4 ± 0.1
KBrO3 + DEM 284.0 ± 14.1*" 246.8 + 24.0,* 2.6 + 1.0
aThree rats per dose were sacrificed 24 hr after IV injection of
KBrO3 (15 mg/kg). DEM (0.7 mL/kg) was injected IP 60 min before
KBrO3 administration.
*p < 0.001.
tp < 0.001.
tp < 0.05 compared to KBrO3-treated controls.
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FIGURE 21. Analysis of 8-OH-dG using an HPLC-ECD system. A)
untreated rat kidney DNA, B) rat kidney DNA, 24 hr after IG
KBrO3 treatment.
normal levels was observed (Fig. 22), suggesting the
presence ofrepair enzymes for 8-OH-dG in the rat kid-
ney. Aslightincrease (- 50%) wasobservedintheliver,
but not significant.
Analysis of 8-OH-dG levels in rats after continuous
oral administration of 500 ppm KBrO3 revealed a sig-
nificant increase in the kidney after 12 weeks of treat-
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FIGURE 22. Quantity of 8-OH-dG in tissue DNA following a single
IG KBrO3 treatment. A) Kidney, B) liver. Points and bars rep-
resent mean values and SD for three independent analyses from
three separate rats.
FIGURE 23. Quantity of 8-OH-dG in tissue DNA following oral
administration of KBrO3. A) Kidney, B) liver. Points and bars
represent mean values and SD for three independent analyses
from three separate rats.
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FIGURE 24. Levels of 8-OH-dG formation in DNA by KBrO3 and/
or methyl linolenate in vitro.
ment, as shown in Figure 23. However, the levels (2-3
residues/105 dG) were much lower than in the single
application experiment and no elevation was apparent
in the liver. These results are compatible with the fact
that the latter organ was not found to be a target organ
in long-term carcinogenicity studies of KBrO3. The
above data clearly showed a positive correlation be-
tween the formation of 8-OH-dG in DNA and KBrO3
carcinogenesis and also strongly implicated an involve-
ment of oxygen radicals in the underlying processes.
KBrO3 was incubated with DNA in vitro at 37°C for 20
hr, and the formation of 8-OH-dG was not observed
(Kasai, personal communication), although it was as-
sociated with a markedly enhanced induction of 8-OH-
dG by methyl linolenate (Fig. 24). Therefore it is con-
ceivable that in the latter case, KBrO3 produced LPO
from methyl linolenate, which resulted in the increased
formation of 8-OH-dG from DNA in vitro. The possi-
bility of artificial nonspecific formation of 8-OH-dG by
KBrO3 during DNA isolation can be ruled out by the
in vitro findings and also as shown previously, by the
fact that BrO3 was not detected in the kidney 24 hr
after IG administration of KBrO3 (72). The 8-OH-dG
produced in DNA can thus be considered as one lesion
with possible direct involvement in carcinogenesis to-
gether with other DNA alterations such as strand scis-
sion or thymine glycol formation. At present, however,
it is not clear which of these DNA lesions is the most
important with regard to KBrO3 carcinogenesis.
General Discussion and Summary
Effects
Although negative results were reported in Great
Britain after administration of bread basal diets made
from flour treated with KBrO3 at levels of75 or 50 ppm
(49,50), chemical analysis revealed that almost all the
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additive is converted to KBr during the normal British
baking process (33,34); the actual exposure was there-
fore negligible. In contrast, KBrO3 is fairly stable when
dissolved in water (6), and the concentrations admin-
istered were considered as the actual dose levels in-
gested by the animals.
The carcinogenicity ofKBrO3 was clearly established
in F344 rats after long-term oral administration in the
drinking water at doses of 500 and 250 ppm (6), with
significantly higher incidences of RCTs in both sexes
and mesotheliomas in males being induced. Subsequent
dose-response studies (14) confirmed the generation of
RCTs even at the 125 ppm level, and these further
demonstrated induction of thyroid follicular adenomas
and adenocarcinomas in males given 500 ppm. It has
therefore been concluded that tubular epithelial cells of
the kidney, mesothelial cells of the peritoneum, and
follicular epithelial cells of the thyroid are target cells
for KBrO3-carcinogenesis.
While the incidences of RCTs in mice (3 strains) and
hamsters were relatively low afterlong-term oraltreat-
ment (11,5), the factthattheRCTs spontaneous develop
in these species is very rare suggests that KBrO3 might
possess cross-species kidneycarcinogenicpotential. The
weak response might be related to the finding that re-
sistant species are less susceptible than rats to the tox-
icity of KBrO3.
In most cases current chronic bioassays are incapable
ofdistinguishing between complete carcinogens, incom-
plete carcinogens (pure initiators), and promoters (83).
There is no doubt that KBrO3 can act as amutagen from
theresults ofboth chromosome aberration and micronu-
cleus tests, although the activity is only very weak in
some microbial assays (61). After a single IG (600 mg/
kgbodyweight) administration ofKBrO3invivo, RCTs
were observed in 4 of41 rats after87weeks (Kurokawa,
unpublished data). This fact, taken together with the
significant eventual rate of RCT induction (50%) when
the compound was administered in drinking water at
500 ppm for only 13 weeks (17), strongly suggests a
positive initiating action of KBrO3.
Furthermore, a promoting action of KBrO3 in renal
tumorigenesis was clearly evident in the two-stage car-
cinogenesis model investigated (5). The threshold level
of KBrO3 for promotion of RCTs appeared to be 15 to
30 ppm in the drinking water (8), although no effects
on tumors of the liver (5,59), skin (7), or GI tract (Ku-
rokawa, unpublished data) were observed. The avail-
able data suggest that KBrO3 should be classified as a
complete carcinogen, possessing bothinitiatingand pro-
moting activities for the rat kidney.
A close similarity between KBrO3-related toxicolog-
ical findings in experimental animals and man has been
noted. Disturbance of functions accompanied with the
histopathological changes in the kidney and the inner
ear have been observed in common in acute KBrO3 in-
toxication (39,41). It should further be borne in mind
that the morphological features of RCTs induced by
KBrO3 in rats, mice, and hamsters are very similar to
those observed in humans, being essentially the same
asthose causedbyapplication ofotherrenalcarcinogens
(6,14). The nephrotoxic action ofKBrO3 in animals was
found to be reversible in the subacute toxicity (10) and
the limited duration protocol experiments (17). In ad-
dition, RCTs and DF were induced by KBrO3 in rats
at doses < 125 ppm, in which chronic nephropathic
changes were only very slight. Therefore, the carcin-
ogenic action of KBrO3 is not dependent on its neph-
rotoxicity.
Although the occurrence of periarteritis in the pan-
creas and accelerated aging pathology of the adrenals
were observed in rats fed on bread made from flour
treated with KBrO3 alone or with KBrO3 and other
oxidizing chemicals (49,50), these findings seem to be
the effects of the bread diet, since they were not ob-
served after oral administration of KBrO3 even at high
dose levels.
Mechanisms
The oxidizingproperties ofKBrO3 are the reasons for
its use as a food additive and industrial chemical. Re-
cently, carcinogenic and promotingpotentials ofseveral
oxidizing chemicals have been revealed by various in
vivo and in vitro studies. In mouse skin carcinogenesis,
for example, benzoyl peroxide was found to be a potent
promoter (84-86) and weak complete carcinogen (7).
The same compound is also suspected as a causative
agent for skin cancer in man (87,88). Hydrogen per-
oxide, lauroylperoxide, decanoylperoxide, cumeneper-
oxide, and sodium chlorite were all demonstrated to be
promoters in the skin system, albeit relatively weak
(7,84,89). Hydrogen peroxide given orally proved to be
a carcinogen inducing duodenal tumors in mice (90) and
apromoterforthe developmentofintestinaltumors (91)
and forestomach papillomas in rats (92). Disturbance of
cellular communication, activation of protein kinase C
and H-ras oncogene, and induction of DNA strand
breaks by oxidizing chemicals have also been recently
reported (93-97).
Itis generallyaccepted thatthe carcinogenic and pro-
moting action of these compounds is caused by gener-
ated active oxygen species (98-101). Furthermore,
studies on oxidant chemicals such as paraquat (102),
ozone (103), and NOx (104), have clearly demonstrated
that they all induce LPO in their target organs, and the
induction of LPO and clastogenic activity are now con-
sidered to be the main factors underlying the carcino-
genic and/or promoting effects shown by these agents.
Based on the oxidizing property ofKBrO3, the levels
ofkidney LPO were examined in animals administered
this compound (18). The findings ofsignificant increases
inkidney LPO levelsinboth adose-dependent andtime-
dependent manner in rats, but not mice or hamsters,
seem to imply a possible relationship between LPO for-
mation in the kidney and the species differences in the
renal toxicity and carcinogenicity of KBrO3.
In addition, a protective role of cysteine and GSH
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against cellular oxidative damage and LPO formation
is well documented. In KBrO3-treated rats, treatment
with cysteine or GSH was similarly associated with a
protective effect in terms ofmortality and various bio-
chemical parameters indicative of nephrotoxicity and
the appearance of lipofuscin pigments, which are con-
sidered to be induced by active oxygen radicals (18).
The fact that GHS and cysteine decreased the numbers
of eosinophilic bodies in the renal tubular cells also im-
plies that they are the result ofcellular oxidative dam-
age by active oxygen radicals (48). On the other hand,
treatment with DEM, a GSH depleter, resulted in an
exacerbation of these lesions. From in vitro studies it
was found that homogenates ofkidney, liver, and RBC
possess degradative activities for BrO3. In studies of
homogenate supernatant by fractionation, GSH was
identified as an involved factor and SH-group com-
pounds showed direct degradative activity when incu-
bated in vitro with BrO3 (73). Thus, it is possible that
protective agents could be depleted by KBrO3 admin-
istration leading to overload and toxicity with high
doses.
The fact that 8-OH-dG, a DNA-damaged product
formed by oxygen-radical generating agents, was de-
tected in the kidney ofrats treated with KBrO3 is note-
worthy in this respect (19). Significantly increased lev-
els of 8-OH-dG were observed after either a single IG
dose or continuous oral administration ofKBrO3 in the
kidney, but not in the liver. In contrast, the noncarcin-
ogenic oxidizing agents sodium chlorite and sodium hy-
pochlorite had no effect on 8-OH-dG formation (19).
These results are therefore in agreement with the hy-
pothesis that formation of 8-OH-dG in tissue DNA is
closely related to organ specificity in carcinogenesis. On
the other hand, incubation ofKBrO3 directly with DNA
in vitro did not result in 8-OH-dG generation, although
it did increase the level of8-OH-dG produced by methyl
linolenate.
In summary, we suggest that KBrO3 produces LPO
from unsaturated fatty acids in vivo through its oxidiz-
ing actions, and the genotoxic activity of KBrO3 may
be the result of DNA damage by LPO and/or active
oxygen radicals generated in the process of LPO for-
mation. Recently we found that hydroxy radicals were
generated in vitro by KBrO3 using electron spin reso-
nance (Kurokawa, unpublished data).
Meanwhile, further research will be needed to clarify
the mechanism ofaction of KBrO3 for induction of per-
itonealmesotheliomas andthyroid follicularcelltumors.
Risk Assessment, Regulatory Status, and
Future Prospects
Toxicologic studies of KBrO3 were reviewed by the
JECFA in 1964 (22) and 1979 (24). As a result, it was
evaluated as one of the safe-to-use food additives and
listed within Class A (1). However, since more recent
studies provided strong evidence ofits carcinogenicity,
it was decided at a 1983 meeting that the previous ac-
ceptanceforthe treatment offlourusedforbakingprod-
ucts should be changed to a temporary acceptance with
a maximum treatment level of 75 mg KBrO3 per kg of
flour, provided that bakery products prepared from
such treated flour could be shown to contain only neg-
ligible residues of KBrO3 (25). No acceptable level was
allocated for use in other foods. In 1982, the Ministry
of Health and Welfare ofJapan had already decided to
lower the maximum treatment level ofKBrO3 for flour
from 50 mg/kg to 30 mg/kg. At the same time, the use
of KBrO3 for the improvement of fish paste products
was banned (26).
The residual levels of KBrO3 at currently acceptable
flour treatment doses have been reported to be negli-
gible in bread (32,34). In fact, no carcinogenic action
was detectable after feeding bread-based diets in long-
term bioassays (49,50). Therefore, in consideration of
the fact that almost all KBrO3 added to the flour is
converted to KBr duringthe bread-baking process (34),
future concern should be directed toward the toxicolog-
ical effects ofKBrin humans (105); so far, no promoting
and only weak mutagenic activities have been demon-
strated for this compound (8,62).
Recently the concept of a virtually safe dose (VSD)
has been proposed as a useful parameter for risk as-
sessment, especially for genotoxic carcinogens (106,
107). The VSD values, based on data for RCTs from
the dose-response studies (Table 6) estimated by dif-
ferent models at a risk level of 106, are listed in Table
23 (12-14). The VSD value of 0.950 ppm KBrO3 was
obtained for RCTs by the Probit model with an inde-
pendent background, with the largest p-value (0.898),
which indicates a good fit.
In the similar evaluation process to IARC, which has
been adopted by the U.S. Environmental Protection
Agency (EPA) (108), this compound will probably be
included in Group B2, because of sufficient evidence
from animal studies and no data from epidemiologic
studies. Alternatively, KBrO3 canbeclassified as a com-
pound showing "clear evidence of carcinogenicity," ac-
Table 23. VSD calculated for RCTs at a risk level of 106.
VSD values by modelsa
Lesion Type of count Probit Logit Weibul Gamma multihit
Renal cell tumor Chi-square value 1.627 2.155 2.472 2.693
p-Value 0.898 0.827 0.781 0.747
VSDb 0.950 0.160 x 10-1 0.481 x 10-2 0.182 x 10-2
aAll models are with independent background.
bKBrO3 dose in ppm, in the drinking water.
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cording to the categorization used by the National Tox-
icology Program (109).
Although active oxygen radicals have been antici-
pated to play an important role in the carcinogenic pro-
cess on the basis of various in vitro studies (110), the
numbers ofinvivomodelsinwhichthishypothesis could
be confirmed are limited. In the case of KBrO3, there
is increasing evidence to suggest that active oxygen
speciesareactuallyinvolvedinitscarcinogenicandtoxic
effects. Therefore we believe that KBrO3 could provide
a key for future investigation of this intriguing area of
carcinogenesis research (111).
Conclusion
KBrO3 exerts nephrotoxic and ototoxic effects in ex-
perimental animals as well as in man. KBrO3 is a gen-
otoxic carcinogen inducing renal cell tumors, mesothe-
liomas, and thyroid follicular cell tumors in rats. KBrO3
is a complete carcinogen havingboth initiating and pro-
moting activities for the development of renal cell tu-
mors. It is highly probable that active oxygen radicals
are involved inthe demonstrated carcinogenic and toxic
effects. Commercial bread made fromflourtreated with
KBrO3 is not carcinogenic in experimental animals,
probably because almost all of the KBrO3 is converted
to KBr during the bread-baking process. KBrO3 is a
useful new compound for analyzing the roles played by
active oxygen radicals in carcinogenesis, both in vivo
and in vitro.
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